Article
In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.
Cancer chemotherapy and pharmacology - 1 Jan 1995
Soudon J, Berlion M, Lucas C, Haddad P, Bizzari J P, Calvo F
Abstract excerpt
The triazinoaminopiperidine derivative S 9788 is a new multidrug-resistance modulator that is currently being evaluated in phase I clinical trials. In this study, the reversal effect of S 9788 in comparison with verapamil was shown in vitro in human T-leukemic CCRF-CEM/VLB cells expressing the multidrug-resistance (MDR) phenotype. S 9788 increased in a dose-dependent manner the cytotoxic activity of doxorubicin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.